Baird Initiates Coverage On Lexeo Therapeutics with Outperform Rating, Announces Price Target of $28
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Brian Skorney has initiated coverage on Lexeo Therapeutics (NASDAQ:LXEO) with an Outperform rating and a price target of $28.
June 13, 2024 | 9:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Brian Skorney has initiated coverage on Lexeo Therapeutics with an Outperform rating and a price target of $28. This positive analyst rating and price target could boost investor confidence and potentially drive the stock price up in the short term.
The initiation of coverage with an Outperform rating and a specific price target of $28 by a reputable analyst can significantly influence investor sentiment. This is likely to result in increased buying activity, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100